A major health insurer, Cigna Corp., has agreed to discontinue the practice of requiring physicians to obtain preauthorization in the prescribing of buprenorphine products. This is a superior decision that will enable physicians to more quickly help patients suffering with opioid addiction.
The Wall Street Journal published this information in their recent business segment and highlighted that the preauthorization process typically introduced a wait time of several days as well as an extensive list of questions that patients must answer in order to be eligible for buprenorphine treatment.
This groundbreaking achievement of removing barriers was accomplished by Eric Schneiderman, the New York State Attorney General. He pressed for answers as to why the insurer’s policy introduced potential barriers to treatment when buprenorphine has been proven to be highly effective and in demand.
Attorney General Schneiderman’s advocacy for opioid addicted patients has opened the door to saving lives while publicizing a need to enable physicians to utilize medication-assisted treatment that is irrefutably beneficial in managing opioid withdrawal, reducing opioid overdose risks, and reducing relapse potential with illicit opiates.